Case Report: Recurrence and Myeloid Neoplasms After Long-Term PARP Inhibitor Use

A 2026 case report from figshare details a single patient's clinical history. The report describes a 49-year-old woman with recurrent ovarian cancer who developed therapy-related myeloid neoplasms after five years of olaparib maintenance therapy. The document is authored by figshare admin karger and shared under a CC-BY-4.0 license.

Use Cases

• Analyze the timeline of disease recurrence and adverse events based on the detailed patient history described.
• Study the clinical presentation and progression of therapy-related myeloid neoplasms based on the case narrative.
• Review treatment protocols and outcomes for recurrent ovarian cancer and subsequent acute myeloid leukemia based on the described interventions.

Strengths

• Provides a detailed, longitudinal clinical timeline spanning from 2010 to the patient's death.
• Focuses on a specific and documented adverse event (therapy-related myeloid neoplasms) linked to long-term PARP inhibitor use.
• Shared under a permissive CC-BY-4.0 license, allowing for reuse and redistribution.

Limitations

• Contains data from a single patient case, limiting statistical generalizability.
• Row count and column-level documentation are absent; data structure must be inferred from the text document.
• The 116.9 KB file size indicates a very limited scope, likely containing only the case report text.

Provenance

Source

figshare

Collection Method

Clinical case documentation.

Time Range

Patient history from 2010 onward, with report published in 2026.

Freshness

Last updated 2026-04-25 11:55:17.